Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Total Liabilities for 11 consecutive years, with $188.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 23.93% to $188.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $188.3 million, a 23.93% increase, with the full-year FY2024 number at $207.3 million, up 38.16% from a year prior.
  • Total Liabilities was $188.3 million for Q3 2025 at Editas Medicine, down from $191.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $207.3 million in Q4 2024 to a low of $110.3 million in Q1 2022.
  • A 5-year average of $150.3 million and a median of $145.9 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 38.71% in 2021, then skyrocketed 38.16% in 2024.
  • Editas Medicine's Total Liabilities stood at $123.8 million in 2021, then grew by 24.06% to $153.6 million in 2022, then decreased by 2.33% to $150.1 million in 2023, then surged by 38.16% to $207.3 million in 2024, then dropped by 9.17% to $188.3 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Total Liabilities are $188.3 million (Q3 2025), $191.4 million (Q2 2025), and $201.2 million (Q1 2025).